Allison Kutner

Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on its definitive merger agreement to acquire scPharmaceuticals for up to $360 million

Cooley advised DigitalOcean Holdings (NYSE: DOCN), a simple, scalable cloud platform that democratizes cloud and artificial intelligence for digital native enterprises around the world, on its $625 million aggregate principal amount of convertible senior notes due 2030 in a private offering pursuant to Rule 144A under the Securities Act of 1933, including the exercise in full of the initial purchasers’ option to purchase up to an additional $75 million aggregate principal amount of the notes.

Cooley advised the underwriters of Heartflow, a leader in artificial intelligence technology for coronary artery disease, in connection with Heartflow’s $364.2 million upsized initial public offering.

Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion.

Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on an up to $500 million strategic financing agreement with funds managed by Blackstone.